Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H2 2012

Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2012', provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) therapeutic pipeline. This report provides information on the therapeutic development for Primary Progressive Multiple Sclerosis (PPMS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Progressive Multiple Sclerosis (PPMS). 'Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Primary Progressive Multiple Sclerosis (PPMS).
- A review of the Primary Progressive Multiple Sclerosis (PPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Primary Progressive Multiple Sclerosis (PPMS) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Primary Progressive Multiple Sclerosis (PPMS) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Primary Progressive Multiple Sclerosis (PPMS) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) 7
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics under Development by Companies 9
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics – Products under Development by Companies 13
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Primary Progressive Multiple Sclerosis (PPMS) Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
AB Science 16
Primary Progressive Multiple Sclerosis (PPMS) – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
ocrelizumab - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AB1010 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Ocrelizumab + Methylprednisolone - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Hydroxyurea - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Trimesta + Norethindrone - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics – Drug Profile Updates 31
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Number of Products Under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2012 7
Products under Development for Primary Progressive Multiple Sclerosis (PPMS) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
F. Hoffmann-La Roche Ltd., H2 2012 15
AB Science, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics – Drug Profile Updates 31

List of Figures
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2012 7
Products under Development for Primary Progressive Multiple Sclerosis (PPMS) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22